Takahiro Tsuge

Scientific Research WorkS Peer Support Group (SRWS-PSG) Osaka Japan.

2 papers in the library · 34 citations · publishing 2023-2025

Papers

Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis.

Journal of Affective Disorders November 8, 2023 I. Terao, Takahiro Tsuge, Kaori Endo et al. 32 citations

For treatment-resistant unipolar depression, intravenous racemic ketamine, intranasal esketamine, aripiprazole, and lithium are all more effective than placebo. Intravenous racemic ketamine is significantly more effective and acceptable than intranasal esketamine and aripiprazole. Unlike intranasal esketamine and aripiprazole, intravenous racemic ketamine does not differ from placebo in tolerability. Lithium and intravenous racemic ketamine show no significant differences in efficacy, tolerability, or acceptability. The sample size for intravenous racemic ketamine was small, and a larger head-to-head trial is needed to clarify whether intravenous racemic ketamine or lithium is superior.

DOI: 10.1016/j.jad.2023.11.023 Medicine

Comparative efficacy and safety of intravenous racemic ketamine, repetitive transcranial magnetic stimulation and electroconvulsive therapy for Stage 2 or higher treatment-resistant depression: A systematic review and network meta-analysis.

PCN reports : psychiatry and clinical neurosciences September 1, 2025 Itsuki Terao, Takahiro Tsuge, Tomoo Sato et al. 2 citations

A network meta-analysis of 35 randomized controlled trials involving 2109 participants compared electroconvulsive therapy (ECT), intravenous racemic ketamine, and repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression. No significant differences emerged in response rate, remission rate, or tolerability among the three treatments. Intravenous ketamine showed significantly higher acceptability than rTMS and ECT. The confidence in the evidence for efficacy, tolerability, and acceptability was very low, largely due to small-study bias. The authors suggest that both ketamine and rTMS may be viable alternatives to ECT, but caution that larger studies are needed to confirm these findings.

DOI: 10.1002/pcn5.70136 Full text Treatment-resistant depression Network meta‐analysis Transcranial magnetic stimulation Treatment resistance +2